Trump Unveils New Plan To Cut Drug Costs And Put Americans First!
President Trump continues to uphold his vows to put Americans first. This time he’s tackling big pharma. Proving yet again ‘putting Americans first’ wasn’t just some campaign promise but a true commitment for him.
“Everyone involved in the broken system — the drug makers, insurance companies, distributors, pharmacy benefit managers, and many others — contribute to the problem,” Mr. Trump said. “Government has also been part of the problem because previous leaders turned a blind eye to this incredible abuse. But under this administration, we are putting American patients first. … I’ve instructed Secretary Azar to begin moving forward on reforms that will bring soaring drug prices back down to Earth.”
“This is a total rip off, and we are ending it,” -President Donald Trump
A BURDEN ON THE AMERICAN PEOPLE: Drug prices are being driven up unfairly, taking a toll on the American people.
- Excessively high drug prices, foreign freeloading, and a system rigged to reward list price increases, are burdening the American people.
- According to the Organization for Economic Co-operation and Development (OECD), the United States had the highest per-capita pharmaceutical spending in 2015.
- Senior citizens pay more in Medicare Part B and Part D because government rules prevent health plans and vendors from negotiating the better deals seen in other markets.
- Some hospitals that receive drug discounts under the 340B program, designed to help safety net facilities, do not provide meaningful levels of charity care to low-income and vulnerable patients, ultimately pushing up drug prices for patients with private health insurance.
- Lower-cost drugs are kept out of the market by drug companies gaming regulatory processes and the patent system in order to unfairly maintain monopolies.
- Lack of transparency in drug pricing benefits special interests and prevents patients from being able to make fully informed decisions about their care.
- Other countries use socialized healthcare to command unfairly low prices from U.S. drug makers. This places the burden of financing drug development largely on American patients and taxpayers, subsidizes foreign consumers, and reduces innovation and the development of new treatments.
- The United States pays more than 70 percent of branded drug profits among OECD countries.
TAKING ACTION TO PUT AMERICAN PATIENTS FIRST: President Donald J. Trump’s blueprint includes new actions and proposals to drive down drug prices for all Americans.
- President Trump’s blueprint will seek to encourage innovation, while also promoting better price competition and addressing foreign freeloading.
Keep Reading More Here: President Donald J. Trump’s Blueprint To Lower Drug Prices